← back to search

Margaryta Pisetska

Azienda Ospedaliera Universitaria Integrata Verona ·
Area of research
Hepatology · Oncology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Liver physiology and pathology, Cancer Immunotherapy and Biomarkers, and Cholangiocarcinoma and Gallbladder Cancer Studies.
h-index
6
citations
1,476
works
6
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗

Recent publications

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
The Lancet Oncology 2025cited by 8position: middledoi
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.
Journal of Clinical Oncology 2024cited by 35position: middledoi
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
The Lancet 2023cited by 645position: middledoi
LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
Annals of Oncology 2022cited by 98position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ann‐Lii Cheng · Xi'an Jiaotong University2 papers (2022–2024)Chi Chen · Jiangsu Hengrui Medicine (China)1 papers (2022–2022)L.S. Chan · Chinese University of Hong Kong1 papers (2022–2022)S. Qin · Beijing Forestry University1 papers (2022–2022)Zhenggang Ren · Ministry of Education of the People's Republic of China1 papers (2024–2024)Weidong Jia · China University of Geosciences1 papers (2024–2024)Z. Ren · Zhongshan Hospital1 papers (2022–2022)A. Vogel · Medizinische Hochschule Hannover1 papers (2022–2022)Shukui Qin · Affiliated Hospital of Southwest Medical University1 papers (2024–2024)Yongdong Jin · Shenzhen University1 papers (2024–2024)X. Liang · Jiangsu Hengrui Medicine (China)1 papers (2022–2022)Ahmed O. Kaseb · The University of Texas MD Anderson Cancer Center1 papers (2024–2024)Stephen L. Chan · California Pacific Medical Center1 papers (2024–2024)A. Kaseb · The University of Texas MD Anderson Cancer Center1 papers (2022–2022)Monika Pazgan−Simon · Regional Children's Clinical Hospital No. 11 papers (2024–2024)Haisong Zhang · North China Electric Power University1 papers (2024–2024)A.V. Sultanbaev · Republican Oncological Clinical Dispensary1 papers (2022–2022)Y. Bai · Shanxi Provincial Cancer Hospital1 papers (2022–2022)Shanzhi Gu · Harbin Medical University1 papers (2024–2024)— · 1 papers (2024–2024)